H3K18 Lactylation-Mediated NOD2 Expression Orchestrates Pyroptosis in Bilirubin-Encephalopathy Astrocytes

Study Background and Research Question

Neonatal hyperbilirubinemia remains a prevalent clinical challenge, with up to 80% of preterm and 60% of term neonates affected. Severe, untreated cases can progress to bilirubin encephalopathy (BE), leading to chronic neurological sequelae such as kernicterus, neurodevelopmental delay, and cerebral palsy. Neuroinflammation has emerged as a key driver in the pathogenesis of BE, yet the molecular mechanisms linking metabolic changes in astrocytes to inflammatory cell death remain incompletely characterized.

Histone lactylation, a novel post-translational modification derived from glycolytic metabolism, has been implicated in immune regulation, but its role in astrocyte biology and BE has not been explored. The central research question posed by Li et al. (2025) is: How does histone H3K18 lactylation modulate gene expression and trigger pyroptosis in astrocytes exposed to unconjugated bilirubin (UCB)?

Key Innovation from the Reference Study

This study is the first to demonstrate that H3K18 lactylation (H3K18la) is significantly upregulated in astrocytes following UCB exposure, both in vitro and in hippocampal tissue from BE rat models. Cutting-edge CUT&Tag chromatin profiling and RNA-seq analyses identify the promoter of nucleotide-binding oligomerization domain 2 (NOD2) as a direct target of H3K18la enrichment. This epigenetic modification enhances NOD2 transcription, which in turn activates downstream MAPK and NF-κB signaling, culminating in pyroptotic cell death and amplification of neuroinflammatory injury.

Methods and Experimental Design Insights

Li et al. employed a combination of primary astrocyte cultures, in vivo BE rat models, and molecular techniques to dissect the metabolic-epigenetic axis underpinning neuroinflammatory damage. Key methodological highlights include:

• Induction of BE in neonatal rats through controlled UCB administration, with subsequent hippocampal tissue analysis.
• Measurement of glycolytic flux and lactate production in astrocytes to confirm metabolic reprogramming under UCB stress.
• Assessment of H3K18la levels via immunoblotting and immunofluorescence in both in vitro and in vivo contexts.
• Application of CUT&Tag coupled with RNA-seq to map H3K18la enrichment genome-wide and identify upregulated genes.
• Pharmacological inhibition of glycolysis to test causality between metabolic flux, histone modification, and pyroptosis.
• Functional interrogation of NOD2’s role using gene knockdown and pathway analysis for downstream signaling cascades.

Protocol Parameters

• UCB treatment: Primary astrocytes were exposed to unconjugated bilirubin at pathophysiologically relevant concentrations for up to 24 hours.
• Glycolysis inhibition: 2-deoxyglucose (2-DG) was applied to block glycolytic flux prior to UCB exposure, decreasing H3K18la and pyroptosis markers.
• Pyroptosis measurement: Membrane pore formation, DNA damage assays, and release of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) were used to quantify cell death and inflammatory status.
• Chromatin mapping: CUT&Tag targeting H3K18la identified enriched promoters, confirmed by RNA-seq for transcriptional impact.
• Gene knockdown: NOD2 silencing was performed to assess its impact on downstream MAPK and NF-κB activation and pyroptotic features.

Core Findings and Why They Matter

The study presents several mechanistic insights with direct implications for BE pathophysiology and broader neuroinflammatory models:

• H3K18la is glycolysis-dependent: UCB-induced astrocyte glycolysis elevates intracellular lactate, which acts as a substrate for H3K18 lactylation.
• NOD2 transcription is epigenetically regulated: Elevated H3K18la at the NOD2 promoter markedly increases its expression, establishing a link between metabolic state and immune gene activation.
• Pyroptosis is exacerbated via NOD2/MAPK/NF-κB axis: Upregulated NOD2 triggers activation of pro-inflammatory signaling pathways, leading to membrane pore formation, cytokine release, and cell lysis typical of pyroptosis.
• Interruption of glycolysis or NOD2 function mitigates injury: Both pharmacological and genetic interventions targeting glycolysis or NOD2 attenuate H3K18la levels, reduce pyroptosis, and dampen neuroinflammation in BE models.

These findings pinpoint the H3K18la/NOD2 axis as a critical regulatory node coupling cellular metabolism to epigenetic and inflammatory outcomes in astrocytes, providing a blueprint for therapeutic intervention beyond traditional antioxidant or anti-inflammatory strategies.

Comparison with Existing Internal Articles

Recent internal resources have highlighted the power of Polyethylenimine Linear (PEI, MW 40,000) as a DNA transfection reagent for in vitro studies and as an enabler of transient gene expression in various cell models. While these works focus on optimizing recombinant protein production and DNA delivery—particularly in HEK-293 and CHO-K1 cells—the current study by Li et al. diverges by addressing epigenetic regulation in primary astrocytes under pathological stress.

For example, Polyethylenimine Linear: Optimizing DNA Transfection in vitro provides actionable guidance for maximizing DNA delivery efficiency, which is foundational for mechanistic studies such as gene knockdown or overexpression experiments deployed by Li et al. The methodological overlap underscores the translational value of high-efficiency gene delivery in probing complex neuroinflammatory pathways.

Limitations and Transferability

Despite its mechanistic rigor, the study presents several limitations that may impact generalizability:

• Model specificity: The findings are derived from neonatal rat models and primary astrocyte cultures, which may not fully capture human neuroinflammatory dynamics or BE heterogeneity.
• Epigenetic landscape complexity: Although H3K18la/NOD2 is identified as a key axis, the broader landscape of histone modifications and non-coding RNA regulation in BE remains unexplored.
• Therapeutic translation: While glycolysis and NOD2 inhibition show promise in preclinical settings, safety and efficacy in humans require further validation.

Nevertheless, the methodological framework—pairing metabolic manipulation with gene expression profiling—can be adapted to other contexts where metabolic-epigenetic crosstalk drives inflammatory injury.

Research Support Resources

To execute similar experimental strategies, particularly gene knockdown or transient gene expression in primary astrocytes or established cell lines, researchers may utilize Polyethylenimine Linear (PEI), MW 40,000 (SKU K1029) as an established DNA transfection reagent for in vitro studies. Its high transfection efficiency, compatibility with serum, and scalability make it suitable for applications ranging from gene overexpression to CRISPR-based epigenetic editing in neurobiology research. APExBIO provides detailed product usage guidance to support robust and reproducible gene delivery workflows.